ovarian cancer: maintenance following frontline bevacizumab
Published 4 years ago • 287 plays • Length 7:24Download video MP4
Download video MP3
Similar videos
-
7:09
biomarker-driven frontline ovarian cancer treatment
-
2:19
dr. arend on fda approval of frontline bevacizumab in ovarian cancer
-
3:42
parp maintenance bevacizumab in ovarian cancer
-
6:03
gog-0218: frontline bevacizumab in ovarian cancer
-
3:47
frontline bevacizumab strategies in ovarian cancer
-
26:02
updates in ovarian cancer: frontline maintenance
-
3:13
dr. herzog on the fda approval of olaparib/bevacizumab as frontline maintenance in ovarian cancer
-
5:25
solo-1: frontline olaparib maintenance therapy in ovarian cancer
-
8:26
the impact of paola-1 on frontline treatment of ovarian cancer
-
6:31
prima: frontline niraparib maintenance therapy in ovarian cancer
-
7:56
maintenance therapy in ovarian cancer
-
5:55
maintenance therapy: parp inhibitor or bevacizumab
-
4:54
bevacizumab in recurrent ovarian cancer
-
4:31
frontline vegf inhibition in advanced ovarian cancer
-
3:40
paola-1: combination maintenance therapy in ovarian cancer
-
7:57
duration of frontline therapy in ovarian cancer
-
2:11
approaching frontline therapy options for ovarian cancer
-
5:41
bevacizumab’s role in recurrent ovarian cancer
-
6:34
bevacizumab’s value in recurrent ovarian cancer